MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Metagenomi Therapeutics, Inc. - Common Stock (NQ:MGX)

1.460 -0.110 (-7.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Metagenomi Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Jefferies Global Healthcare Conference in London
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors
Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping pipeline and business strategy 
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at Upcoming Scientific Meetings
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
Via AB Newswire
Topics Artificial Intelligence Government
News headline image
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Announces New Appointment to its Board of Directors
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
From Metagenomi, Inc.
Via GlobeNewswire
News headline image
FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
MGX Deadline: Rosen Law Firm Urges Metagenomi, Inc. (NASDAQ: MGX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Metagenomi, Inc. (MGX)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
DEADLINE NEXT WEEK: Berger Montague Advises Metagenomi (NASDAQ: MGX) Investors to Contact the Firm Before November 25, 2024
From Berger Montague
Via GlobeNewswire
News headline image
METAGENOMI, INC. (NASDAQ: MGX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Metagenomi, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Metagenomi, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
METAGENOMI (NASDAQ: MGX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by November 25, 2024
From Berger Montague
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi
From Faruqi & Faruqi LLP
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story